Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ABVC BioPharma, Inc. (ABVC)
USD1.28
-0.06 (-4.48%)
US NASDAQ Healthcare Biotechnology
Address
44370 Old Warm Springs Boulevard 94538
Fremont, CA, US
Fremont, CA, US
CEO
Uttam Yashwant Patil
Website
abvcpharma.com
IPO
2004-11-10
CIK 1173313 ISIN US00091F3047
Description
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| BioLite | 2018-07-23 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.28
-0.06 (-4.48%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
135.6K
Beta
0.57
Float Shares
13.42M
Free Float %
92.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.83% | +0.94% | -18.94% | -33.13% | -63.36% | -49.77% | -22.46% | -85.40% | -98.00% | -99.70% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
1.28
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-5.69
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+56.2% ★
-
EPS growth Biotechnology: +29.7%+7.1% Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-968.4%
-
EBIT margin Biotechnology: +0.0%-898.5%
-
ROIC Biotechnology: -16.1%-44.6% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+99.2% Q1'26: +70.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.52× Q1'26: -0.43× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
483.0K
est: 537.6K (-10.1%)
|
355.8K
est: 588.9K (-39.6%)
|
969.8K
est: 394.1K (+146.1%)
|
152.4K
est: 697.8K (-78.2%)
|
509.6K
est: 14.51M (-96.5%)
|
796.0K
est: 4.17M (-80.9%)
|
35.28M
35.28M – 35.28M
+745.5% YoY
|
| EBITDA |
-10.37M
est: -537.6K (-1,829.4%)
|
-10.97M
est: -588.9K (-1,763.1%)
|
-15.20M
est: -394.1K (-3,755.9%)
|
-6.33M
est: -697.8K (-807.3%)
|
-4.34M
est: -14.51M (+70.1%)
|
-6.65M
est: -4.17M (-59.3%)
|
-35.28M
-35.28M – -35.28M
-745.5% YoY
|
| EBIT |
-10.41M
est: -537.6K (-1,836.3%)
|
-10.98M
est: -588.9K (-1,765.2%)
|
-15.22M
est: -394.1K (-3,762.0%)
|
-6.71M
est: -697.8K (-861.8%)
|
-4.54M
est: -14.51M (+68.7%)
|
-7.15M
est: -4.17M (-71.4%)
|
-35.28M
-35.28M – -35.28M
-745.5% YoY
|
| Net Income |
-9.79M
est: -39.69M (+75.3%)
|
-12.84M
est: -26.85M (+52.2%)
|
-16.42M
est: -60.70M (+72.9%)
|
-7.79M
est: -23.35M (+66.6%)
|
-4.90M
est: -102.33M (+95.2%)
|
-7.91M
est: -106.98M (+92.6%)
|
30.23M
30.23M – 30.23M
+128.3% YoY
|
| SGA |
8.42M
est: 11.65M (-27.7%)
|
11.05M
est: 12.76M (-13.4%)
|
13.10M
est: 8.54M (+53.5%)
|
5.55M
est: 15.12M (-63.3%)
|
5.03M
est: 287.65M (-98.2%)
|
6.53M
est: 82.70M (-92.1%)
|
699.29M
699.29M – 699.29M
+745.5% YoY
|
| EPS |
-5.00
est: -3.40 (-47.1%)
|
-5.10
est: -2.30 (-121.7%)
|
-5.20
est: -5.20 (+0.0%)
|
-1.80
est: -2.00 (+10.0%)
|
-0.42
est: -4.40 (+90.5%)
|
-0.39
est: -4.60 (+91.5%)
|
1.30
1.30 – 1.30
+128.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.83M
OE per share TTM
-0.16
Owner's Yield
-11.18%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
613.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
6
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Jiang | 7.91M | 24.50% | 7.91M | — | 7.91M | — | IN | USA | 2022-07-12 | ↗ |
| 2 | Fairmount Five, LLC90-0662543 | 3.50M | 77.40% | 37.28M | — | 37.28M | — | CO | Michigan | 2012-03-01 | ↗ |
| 3 | Jeff Easton | 385.0K | 9.90% | 385.0K | — | 385.0K | — | IN | United States | 2023-08-07 | ↗ |
| 4 | Lind Global Fund II LP | 385.0K | 9.90% | 385.0K | — | 385.0K | — | PN | Delaware | 2023-08-07 | ↗ |
| 5 | Lind Global Partners II LLC | 385.0K | 9.90% | 385.0K | — | 385.0K | — | OO | Delaware | 2023-08-07 | ↗ |
| 6 | Bonner John | 122.00 | 12.60% | 2.03M | — | 2.03M | 10.00 | IN | OR PLACE OF ORGANIZATION | 2011-09-30 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 287.0K | 0.05% |
| 2 | Vanguard Total Stock Market ETF VTI | 0.00% | 29.4K | 0.03% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 62.48 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 171.54 | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 12.67 | 0.17% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 64.16 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 34.88 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 14.00 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 1.58 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.22 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-20 | Jiang Shuling | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 7,908,805 | — | ↗ |
| 2021-11-08 | Tseng Shih-Chen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-02 | Sakamoto Norimi | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-08-02 | Odaira Yoshinobu | Director | — | D | Common Stock | 0 | 0.00 | — | 163,702 | — | ↗ |
| 2021-08-02 | Miao Shin-Yu | Director | — | I | Common Stock | 0 | 0.00 | — | 67,378 | — | ↗ |
| 2021-08-02 | King Chi-Hsin Richard | Officer | — | D | Common Stock | 0 | 0.00 | — | 869 | — | ↗ |
| 2021-08-02 | Jiang Tsung Shann | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 12,103,971 | — | ↗ |
| 2021-08-02 | Jiang Tsang Ming | Director | — | D | Common Stock | 0 | 0.00 | — | 6,067 | — | ↗ |
| 2021-08-02 | Jiang Eugene | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 732,716 | — | ↗ |
| 2021-08-02 | Jiang Chang-Jen | Director | — | I | Common Stock | 0 | 0.00 | — | 5,949 | — | ↗ |
| 2021-08-02 | Doong Howard | Officer | — | D | Common Stock | 0 | 0.00 | — | 18,404 | — | ↗ |
| 2021-08-02 | Chou Yen-Hsin | Director | — | D | Common Stock | 0 | 0.00 | — | 5,679 | — | ↗ |
| 2021-08-02 | An Chihliang | Officer | — | D | Common Stock | 0 | 0.00 | — | 13,334 | — | ↗ |
| 2015-09-08 | Lazar Shulamit | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 60,000,000 | — | ↗ |
| 2012-01-27 | Stolz Kevin Patrick | Officer | A-Award | A | Common Stock | 6,250 | 0.00 | — | 6,250 | — | ↗ |
| 2012-01-01 | Ramsey Sally Judith | Officer | — | D | Options (Right to Purchase) | 150,000 | 2.00 | 300.0K | 0 | — | ↗ |
| 2011-09-15 | Crockett Robert G | Officer | — | D | Options (Right to Purchase) | 110,000 | 1.05 | 115.5K | 0 | — | ↗ |
| 2011-09-13 | Rempinski Daniel | Director | — | D | Stock Options | 100,000 | 0.05 | 5.0K | 0 | — | ↗ |
| 2011-09-13 | Orchard James | Director | — | D | Stock Options | 100,000 | 0.05 | 5.0K | 0 | — | ↗ |
| 2011-06-29 | Juliano James | Director | — | D | Stock Options | 100,000 | 0.10 | 10.0K | 0 | — | ↗ |
| 2011-05-25 | Krotine Frank Thomas | Officer | A-Award | A | Stock Options | 300,000 | 0.20 | 60.0K | 300,000 | — | ↗ |
| 2011-05-11 | Stolz Kevin Patrick | Officer | A-Award | A | Stock Options | 50,000 | 0.20 | 10.0K | 50,000 | — | ↗ |
| 2011-05-11 | Ramsey Sally Judith | Director / Officer | A-Award | A | Stock Options | 2,100,000 | 0.20 | 420.0K | 2,100,000 | — | ↗ |
| 2011-05-11 | IANNOTTI DANIEL V | Officer | A-Award | A | Stock Options | 300,000 | 0.20 | 60.0K | 300,000 | — | ↗ |
| 2011-05-11 | Crockett Robert G | Officer | A-Award | A | Stock Options | 1,800,000 | 0.20 | 360.0K | 1,800,000 | — | ↗ |
| 2010-08-27 | Campion Donald C | Director | — | D | Options (Right to Purchase) | 25,000 | 3.00 | 75.0K | 0 | — | ↗ |
| 2010-08-12 | Juliano James | Director / 10% Owner | A-Award | A | Stock Options | 100,000 | 0.10 | 10.0K | 100,000 | — | ↗ |
| 2010-06-29 | Smith J.B. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-06-29 | Juliano James | Director | — | I | Common Stock | 0 | 0.00 | — | 5,200,000 | — | ↗ |
| 2010-06-29 | DelMonaco, Jr. Rocco | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2010-05-11 | Nirta Joseph | Director | P-Purchase | A | Common Stock | 10,000 | 0.15 | 1.5K | 10,000 | — | ↗ |
| 2010-03-23 | IANNOTTI DANIEL V | Officer | A-Award | A | Options to acquire common stock | 220,000 | 0.51 | 112.2K | 220,000 | — | ↗ |
| 2010-03-22 | Nirta Joseph | Director | P-Purchase | A | Common Stock | 2,000 | 0.26 | 520.00 | 2,000 | — | ↗ |
| 2010-01-13 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Convertible Preferred Shares, Series B | 55 | 0.05 | 2.75 | 3,328 | — | ↗ |
| 2009-12-16 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Convertible preferred shares, Series B | 31 | 0.05 | 1.55 | 3,223 | — | ↗ |
| 2009-11-13 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Common Stock | 714,286 | 50,000.00 | 35.71B | 16,585,538 | — | ↗ |
| 2009-10-02 | Stromback Richard Dean | 10% Owner | P-Purchase | A | Warrant No. 1 | 14,400 | 0.42 | 6.0K | 24,400 | — | ↗ |
| 2009-10-01 | Stromback Richard Dean | 10% Owner | P-Purchase | A | Preferred Shares | 240 | 0.42 | 100.80 | 595,828 | — | ↗ |
| 2009-09-21 | Krotine Frank Thomas | Officer | A-Award | A | Common Stock | 169,000 | 0.51 | 86.2K | 510,217 | — | ↗ |
| 2009-09-21 | IANNOTTI DANIEL V | Officer | A-Award | A | Common Stock | 70,000 | 0.51 | 35.7K | 400,000 | — | ↗ |
| 2009-09-21 | Crockett Robert G | Officer | A-Award | A | Common Stock | 670,000 | 0.51 | 341.7K | 1,000,000 | — | ↗ |
| 2009-09-17 | Smith J.B. | Director | — | D | Options (Right to Purchase) | 100,000 | 1.05 | 105.0K | 0 | — | ↗ |
| 2009-09-17 | DelMonaco, Jr. Rocco | Director | — | D | Options (Right to Purchase) | 100,000 | 1.05 | 105.0K | 0 | — | ↗ |
| 2009-09-15 | Crockett Robert G | Officer | — | D | Options (Right to Purchase) | 330,000 | 1.05 | 346.5K | 0 | — | ↗ |
| 2009-09-14 | Smith J.B. | Director / 10% Owner | J-Other | D | Common Stock | 50,000 | 2.00 | 100.0K | 1,031,000 | — | ↗ |
| 2009-08-31 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Common Stock | 192,308 | 50,000.00 | 9.62B | 18,430,752 | — | ↗ |
| 2009-08-19 | Smith J.B. | Director / 10% Owner | G-Gift | D | Common Stock | 300,000 | 0.00 | — | 17,575,000 | — | ↗ |
| 2009-08-11 | IANNOTTI DANIEL V | Officer | — | D | Options to acquire common stock | 220,000 | 0.51 | 112.2K | 0 | — | ↗ |
| 2009-07-01 | Tracy Adam Samuel | Officer | — | D | Options (Right to Purchase) | 25,000 | 2.00 | 50.0K | 0 | — | ↗ |
| 2009-06-10 | Smith J.B. | Director / 10% Owner | P-Purchase | A | 5% Convertible Preferred Stock, Series B | 20 | 20,000.00 | 400.0K | 336 | — | ↗ |
| 2009-06-02 | Smith J.B. | Director / 10% Owner | P-Purchase | A | 5% Convertible Preferred Stock | 55 | 55,000.00 | 3.03M | 2,436 | — | ↗ |
| 2009-05-21 | MORGAN DAVID W | Officer | — | D | Options (Right To Purchase) | 225,000 | 1.05 | 236.3K | 0 | — | ↗ |
| 2009-04-29 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Warrants to acquire common stock | 17,000 | 0.75 | 12.8K | 1,178,500 | — | ↗ |
| 2009-04-14 | Smith J.B. | Director / 10% Owner | P-Purchase | A | 5% Convertible Preferred Stock | 21 | 21,000.00 | 441.0K | 2,347 | — | ↗ |
| 2009-03-26 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Warrants to acquire common stock | 40,000 | 0.75 | 30.0K | 1,151,000 | — | ↗ |
| 2009-03-26 | Ramsey Sally Judith | Director / 10% Owner | P-Purchase | A | Warrants to acquire common stock | 40,000 | 0.75 | 30.0K | 1,151,000 | — | ↗ |
| 2009-03-17 | Smith J.B. | Director | — | I | Options (Right to Purchase) | 531,000 | 1.05 | 557.6K | 0 | — | ↗ |
| 2009-03-10 | Smith J.B. | Director / 10% Owner | P-Purchase | A | 5% Convertible Preferred Stock | 23 | 23,000.00 | 529.0K | 2,246 | — | ↗ |
| 2009-02-26 | Smith J.B. | Director / 10% Owner | P-Purchase | A | 5% Convertible Preferred Stock | 40 | 40,000.00 | 1.60M | 2,223 | — | ↗ |
| 2009-02-11 | Smith J.B. | Director / 10% Owner | P-Purchase | A | 5% Convertible Preferred Stock | 30 | 30,000.00 | 900.0K | 2,158 | — | ↗ |
| 2009-02-10 | Smith J.B. | Director / 10% Owner | J-Other | A | 5% Convertible Preferred Stock | 24 | 0.00 | — | 2,128 | — | ↗ |
| 2009-01-23 | Stromback Richard Dean | Director / 10% Owner | S-Sale | D | Common Stock | 4,000,000 | 1.00 | 4.00M | 10,637,500 | — | ↗ |
| 2009-01-23 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Options to acquire Common Stock | 500,000 | 0.90 | 450.0K | 1,031,000 | — | ↗ |
| 2008-12-19 | IANNOTTI DANIEL V | Officer | A-Award | A | Common Stock | 330,000 | 0.66 | 217.8K | 330,000 | — | ↗ |
| 2008-11-01 | Krotine Frank Thomas | Director / Officer | — | D | Options (Right to Purchse) | 240,980 | 2.00 | 482.0K | 0 | — | ↗ |
| 2008-10-20 | Nirta Joseph | Director | A-Award | A | Options to acquire common stock | 100,000 | 1.04 | 104.0K | 100,000 | — | ↗ |
| 2008-09-26 | Smith J.B. | Director | P-Purchase | A | Common Stock Warrants (Right To Purchase) | 375,000 | 0.75 | 281.3K | 1,005,000 | — | ↗ |
| 2008-09-17 | Stolz Kevin Patrick | Officer | A-Award | A | Options (Right to Purchase) | 10,000 | 1.05 | 10.5K | 85,000 | — | ↗ |
| 2008-09-17 | Smith J.B. | Director / 10% Owner | P-Purchase | A | Options to acquire Common Stock | 100,000 | 1.05 | 105.0K | 100,000 | — | ↗ |
| 2008-09-15 | Smith J.B. | Director | — | I | Common Stock | 0 | 0.00 | — | 3,305 | — | ↗ |
| 2008-08-28 | Smith J.B. | Director | — | I | Common Stock Warrants (Right to Purchase) | 630,000 | 0.75 | 472.5K | 0 | — | ↗ |
| 2008-08-18 | Stromback Richard Dean | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 1,500,000 | 1.00 | 1.50M | 14,637,500 | — | ↗ |
| 2008-08-11 | IANNOTTI DANIEL V | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-07-28 | Juliano James | Director | — | I | Warrants | 1,178,500 | 0.75 | 883.9K | 0 | — | ↗ |
| 2008-04-03 | Stolz Kevin Patrick | Officer | A-Award | A | Options (Right to Purchase) | 25,000 | 1.05 | 26.3K | 25,000 | — | ↗ |
| 2008-03-01 | Stromback Richard Dean | Director / 10% Owner | — | D | Options (Right to Purchase) | 10,000 | 2.00 | 20.0K | 0 | — | ↗ |
| 2008-03-01 | Liebig Robert W | Director | — | D | Options (Right to Purchase) | 100,000 | 2.00 | 200.0K | 0 | — | ↗ |
| 2008-03-01 | Krotine Frank Thomas | Director / Officer | — | D | Options (Right to Purchase) | 10,000 | 2.00 | 20.0K | 0 | — | ↗ |
| 2008-02-01 | Stolz Kevin Patrick | Officer | — | D | Options (Right to Purchase) | 25,000 | 2.00 | 50.0K | 0 | — | ↗ |
| 2007-08-27 | Campion Donald C | Director | — | D | Options (Right to Purchase) | 25,000 | 3.00 | 75.0K | 0 | — | ↗ |
| 2007-07-30 | Stromback Richard Dean | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 16,135,000 | — | ↗ |
| 2007-07-30 | Ramsey Sally Judith | Officer | — | D | Sally Ramsey | 0 | 0.00 | — | 3,000,000 | — | ↗ |
| 2007-07-30 | Krotine Frank Thomas | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 10,000 | — | ↗ |
| 2007-06-26 | Juliano James | Director | — | I | Stock Options | 500,000 | 0.90 | 450.0K | 0 | — | ↗ |
| 2007-03-01 | Stromback Richard Dean | Director / 10% Owner | P-Purchase | A | Options to acquire Common Stock | 10,000 | 2.00 | 20.0K | 10,000 | — | ↗ |
| 2007-01-01 | Ramsey Sally Judith | Officer | A-Award | A | Options to acquire Common Stock | 450,000 | 2.00 | 900.0K | 450,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-4.5K
Shares Outstanding
14.49M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2042 | Uttam Patil | — | — | 107.6K | — | — | — | 107.6K | 100.00% | ↗ |
| 2 | 2025 | Eugene Jiang | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 3 | 2025 | Tsung-Shann Jiang | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 4 | 2024 | Eugene Jiang | 200.0K | — | 215.2K | — | — | — | 415.2K | 51.84% | ↗ |
| 5 | 2024 | Tsung-Shann Jiang | 200.0K | — | 153.7K | — | — | — | 353.7K | 43.46% | ↗ |
| 6 | 2024 | Leeds Chow | 34.0K | — | 76.9K | — | — | — | 110.6K | 69.52% | ↗ |
| 7 | 2024 | Uttam Patil | — | — | 107.6K | — | — | — | 107.6K | 100.00% | ↗ |
| 8 | 2024 | Richard Chi-Hsin King | 90.6K | — | — | — | — | — | 90.6K | 0.00% | ↗ |
| 9 | 2023 | Eugene Jiang | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 10 | 2023 | Tsung-Shann Jiang | 200.0K | — | — | — | — | — | 200.0K | 0.00% | ↗ |
| 11 | 2023 | Leeds Chow | 180.0K | — | — | — | — | — | 180.0K | 0.00% | ↗ |
| 12 | 2023 | Richard Chi-Hsin King | 90.6K | — | — | — | — | — | 90.6K | 0.00% | ↗ |
| 13 | 2022 | Richard Chi-Hsin King | 200.0K | — | — | 248.4K | — | — | 448.4K | 55.40% | ↗ |
| 14 | 2022 | Howard Doong | 200.0K | — | — | 248.4K | — | — | 448.4K | 55.40% | ↗ |
| 15 | 2022 | Eugene Jiang | 200.0K | — | — | 248.4K | — | — | 448.4K | 55.40% | ↗ |
| 16 | 2022 | Tsung-Shann Jiang | 200.0K | — | — | 248.4K | — | — | 448.4K | 55.40% | ↗ |
| 17 | 2022 | Chihliang An | 133.3K | — | — | 248.4K | — | — | 381.7K | 65.07% | ↗ |
| 18 | 2022 | Leeds Chow | 130.0K | — | — | — | — | — | 130.0K | 0.00% | ↗ |
| 19 | 2021 | Howard Doong | 200.0K | — | — | 836.0K | — | — | 1.04M | 80.70% | ↗ |
| 20 | 2021 | Richard Chi-Hsin King | 200.0K | — | — | 661.8K | — | — | 861.8K | 76.79% | ↗ |
| 21 | 2021 | Chihliang An | 200.0K | — | — | 487.7K | — | — | 687.7K | 70.92% | ↗ |
| 22 | 2021 | Tsung-Shann Jiang | 200.0K | — | — | 62.7K | — | — | 262.7K | 23.87% | ↗ |
| 23 | 2021 | Eugene Jiang | 200.0K | — | — | 62.7K | — | — | 262.7K | 23.87% | ↗ |
| 24 | 2021 | Leeds Chow | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 25 | 2020 | Howard Doong | 200.0K | — | — | 234.8K | — | — | 434.8K | 54.00% | ↗ |
| 26 | 2020 | Richard Chi-Hsin King | 200.0K | — | — | 234.8K | — | — | 434.8K | 54.00% | ↗ |
| 27 | 2020 | Eugene Jiang | 200.0K | — | — | 207.6K | — | — | 407.6K | 50.93% | ↗ |
| 28 | 2020 | Chihliang An | 200.0K | — | — | 156.5K | — | — | 356.5K | 43.90% | ↗ |
| 29 | 2020 | Tsung-Shann Jiang | 200.0K | — | — | 106.7K | — | — | 306.7K | 34.80% | ↗ |
| 30 | 2010 | Robert G. Crockett CEO | 200.0K | — | — | — | — | 22.0K | 222.0K | 0.00% | ↗ |
| 31 | 2010 | Daniel V. Iannotti VP, General Counsel Secretary | 105.9K | — | — | — | — | 17.4K | 123.3K | 0.00% | ↗ |
| 32 | 2010 | Sally Ramsey Vice President New Product Development | 73.8K | — | — | — | — | 17.4K | 91.6K | 0.00% | ↗ |
| 33 | 2010 | F. Thomas Krotine President Chief Operating Officer | 63.6K | — | — | — | — | 6.2K | 69.8K | 0.00% | ↗ |
| 34 | 2010 | Kevin P. Stolz Chief Financial Officer | 42.0K | — | — | — | — | 12.7K | 54.7K | 0.00% | ↗ |
| 35 | 2009 | Robert G. Crockett CEO | 200.0K | — | — | — | — | 21.3K | 633.1K | 0.00% | ↗ |
| 36 | 2009 | Daniel V. Iannotti VP, General Counsel Secretary | 115.0K | — | — | — | — | 17.0K | 412.3K | 0.00% | ↗ |
| 37 | 2009 | F. Thomas Krotine President Chief Operating Officer | 50.7K | — | — | — | — | 8.9K | 163.8K | 0.00% | ↗ |
| 38 | 2009 | Kevin P. Stolz Chief Financial Officer | 67.7K | — | — | — | — | 22.4K | 108.4K | 0.00% | ↗ |
| 39 | 2009 | Sally Ramsey Vice President New Product Development | 89.2K | — | — | — | — | 17.3K | 106.4K | 0.00% | ↗ |
| 40 | 2008 | Kevin P. Stolz Chief Financial Officer | 133.3K | — | — | — | — | 16.3K | 310.2K | 0.00% | ↗ |
| 41 | 2008 | Robert G. Crockett CEO | 8.3K | — | — | — | — | 1.3K | 263.0K | 0.00% | ↗ |
| 42 | 2008 | Sally Ramsey Vice President New Product Development | 195.8K | — | — | — | — | 12.6K | 208.4K | 0.00% | ↗ |
| 43 | 2008 | F. Thomas Krotine President Chief Operating Officer | 160.0K | — | — | — | — | 7.3K | 167.3K | 0.00% | ↗ |
| 44 | 2008 | Daniel V. Iannotti VP, General Counsel Secretary | 21.1K | — | — | — | — | 1.6K | 22.6K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eugene Jiang | Chairman & Chief Business Officer | 200.0K | male |
| Tsung-Shann Jiang | Chief Scientific Officer, Chief Strategy Officer & Director | 200.0K | — |
| Uttam Yashwant Patil | Chief Executive Officer & Interim Chief Financial Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABVC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
